FOLFOXIRI—improving outcomes of metastatic colorectal cancer

被引：0
|
作者：
Alessia Errico
机构：
来源：
Nature Reviews Clinical Oncology | 2014年 / 11卷 / 12期
关键词：
D O I：
10.1038/nrclinonc.2014.194
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：684 / 684
相关论文
共 50 条
  • [21] Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JS']JSCCR-TRIPON study
    Yamamoto, Yoshiyuki
    Yukami, Hiroki
    Yamaguchi, Tatsuro
    Ohori, Hisatsugu
    Nagasu, Sachiko
    Kagawa, Yoshinori
    Sugimoto, Naotoshi
    Sonoda, Hiromichi
    Yamazaki, Kentaro
    Takashima, Atsuo
    Okuyama, Hiroyuki
    Hasegawa, Hiroko
    Kondo, Chihiro
    Baba, Eishi
    Matsumoto, Toshihiko
    Kawamoto, Yasuyuki
    Kataoka, Masato
    Shindo, Yoshiaki
    Ishikawa, Toshiaki
    Esaki, Taito
    Kito, Yosuke
    Sato, Takeo
    Funakoshi, Taro
    Yamaguchi, Toshifumi
    Shimada, Yasuhiro
    Moriwaki, Toshikazu
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024,
  • [22] Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (mCRC): An agestratified analysis.
    Vassilev, Zdravko
    Fan, Xiaozhou
    Ostojic, Helene
    Xu, Julie
    Barzi, Afsaneh
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 64 - 64
  • [23] FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
    Antoniotti, Carlotta
    Vetere, Guglielmo
    Cremolini, Chiara
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (18)
  • [24] An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone
    Rizzo, Alessandro
    Palloni, Andrea
    Frega, Giorgio
    Abbati, Francesca
    De Lorenzo, Stefania
    Brocchi, Stefano
    Brandi, Giovanni
    [J]. ANTI-CANCER DRUGS, 2019, 30 (04) : 428 - 430
  • [25] Improving treatment options for metastatic colorectal cancer
    Laffman-Johnson, Elise
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (06) : 619 - 619
  • [26] Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice
    Keisuke Kazama
    Manabu Shiozawa
    Masakatsu Numata
    Nobuhiro Sugano
    Sumito Sato
    Mamoru Uchiyama
    Maho Sato
    Toru Aoyama
    Hiroshi Tamagawa
    Takashi Oshima
    Norio Yukawa
    Yasushi Rino
    [J]. International Journal of Colorectal Disease, 2022, 37 : 337 - 348
  • [27] Modified FOLFOXIRI regimen as salvage treatment for metastatic colorectal cancer patients: A retrospective study.
    Wang, Zhen
    Zheng, Song
    Xu, Xifeng
    Qian, Yuan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] From clinical trial to bedside: Triplet chemotherapy (FOLFOXIRI-B) in metastatic colorectal cancer
    Bol, G. M.
    van Nassau, S. C. M. W.
    Bond, M.
    Scheerman, I.
    Breeschoten, J. V.
    Kessels, R.
    Valkenburg-Van Iersel, L.
    Verheul, H. M. W.
    Buffart, T.
    Mekenkamp, L. J. M.
    Lemmens, V.
    Koopman, M.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S546 - S546
  • [29] Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?
    Nipp, Ryan D.
    Ryan, David P.
    [J]. ONCOLOGIST, 2015, 20 (03): : 236 - 238
  • [30] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Sensi, E.
    Schirripa, M.
    Michelucci, A.
    Pfanner, E.
    Brunetti, I.
    Lupi, C.
    Antoniotti, C.
    Bergamo, F.
    Lonardi, S.
    Zagonel, V.
    Simi, P.
    Fontanini, G.
    Falcone, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 57 - 63
12345